Lung Cancer Liquid Biopsy Using Extracellular Vesicles in Early Stages
With a 5-year survival rate of ∼20%, lung cancer is one of the most prevalent and deadly cancers....
Read More
Hematology/Oncology, BreakingMed
New Multiple Myeloma Staging System Provides Additional Data
Despite advances in multiple myeloma (MM) treatment, research suggests that survival outcomes can...
Read More
Black Women Underrepresented in Immunotherapy Trials
“Racial inequity in healthcare delivery and outcomes in the United States is well-documented, and...
Read More
First Cell-Based Gene Therapy Gets FDA Nod for Multiple Myeloma
Idecabtagene vicleucel indicated for patients who did not respond to previous therapy WASHINGTON...
Read More
Safety and efficacy of mitapivat in pyruvate kinase deficiency
Pyruvate kinase deficiency (PKD) is a deficiency of enzyme pyruvate kinase that leads to an easy...
Read MoreRoxadustat treatment for anemia in patients undergoing long-term dialysis
Anemia is a condition in which the body lacks enough healthy blood cells to carry adequate oxygen to the body tissues. Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that increases the endogenous...
Read More
ASCO: Breast Cancer Brain Mets Treated with Tucatinib
Addition of agent to chemotherapy improves survival The risk of death or progression of brain...
Read More
ASCO: Larotrectinib Produces Durable Responses
TRK fusion targets multiple cancers Patients diagnosed with a variety of advanced cancers —...
Read More
ASCO: Survival Benefit Emerges in ARAMIS
Darolutamide better in non-metastatic castration-resistant prostate cancer Men diagnosed with...
Read More
ASCO: Consultant Palliation Improves AML Quality of Life
Early referral linked to better psychological outcomes Referring a patient diagnosed with acute...
Read More
ASCO: Gastric Cancer Patients Respond to Trastuzumab Deruxtecan
Overall survival also extended with conjugate treatment In a small, phase II trial, patients with...
Read More
ASCO: Oral GnRH Antagonist Superior to Leuprolide Injection in Prostate Cancer
HERO findings also confirm fewer cardiovascular events with relugolix More than 96% of men with...
Read More